The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis
- PMID: 31391030
- PMCID: PMC6686246
- DOI: 10.1186/s12885-019-5987-4
The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis
Abstract
Background: Increasing evidence revealed that high expression level of lncRNA SNHG1 was associated with the unfavorable prognosis of cancer and maybe used as a valuable biomarker for cancer patients. The present meta->analysis is to analyze existing data to reveal potential clinical application of SNHG1 on cancer prognosis and tumor progression. All of the included studies were collected through a variety of retrieval strategies. And the articles were qualified by MOOSE and PRISMA checklists.
Methods: Up to Mar 20, 2018, literature collection was performed by comprehensive search through electronic databases, including the Cochrane library, PubMed, Embase, Web of science, Springer, Science direct, and three Chinese databases: CNKI, Weipu, and Wanfang. We analyzed 14 studies that met the criteria, and concluded that the increased SHNG1 level was correlated with poor OS and tumor progression.
Results: The combined results indicated that elevated SNHG1 expression level was significantly associated with poor OS (HR = 2.06, 95% CI: 1.69-2.52, P < 0.01) and PFS (HR = 2.78, 95% CI: 1.69-4.55, P < 0.01) in various cancers. Moreover, the promoted SNHG1 expression was also associated with tumor progression ((III/IV vs. I/II: HR = 1.89, 95% CI: 1.53-2.34, P < 0.01). In stratified analyses, a significantly unfavorable association of elevated lncRNA SNHG1 and OS was observed in both digestive system (HR = 2.04, 95% CI: 1.56-2.68, P < 0.01) and non-digestive system (HR = 2.09, 95% CI: 1.55-2.83, P < 0.01) cancer patients.
Conclusions: The present analysis indicated that the increased SNHG1 is associated with poor OS in patients with general tumors and may be served as a useful prognostic biomarker.
Keywords: Cancer; Long non-coding RNA; Prognosis; SNHG1.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
The Value of lncRNA GHET1 as a Prognostic Factor for Survival of Chinese Cancer Outcome: A Meta-Analysis.Dis Markers. 2019 Dec 1;2019:5824190. doi: 10.1155/2019/5824190. eCollection 2019. Dis Markers. 2019. PMID: 31885739 Free PMC article.
-
Upregulation of lncRNA SNHG1 is associated with metastasis and poor prognosis in cancers: A meta-analysis.Medicine (Baltimore). 2019 Apr;98(16):e15196. doi: 10.1097/MD.0000000000015196. Medicine (Baltimore). 2019. PMID: 31008944 Free PMC article.
-
The Prognostic Value of Expression of the Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) in Patients with Solid Malignant Tumors: A Systematic Review and Meta-Analysis.Med Sci Monit. 2018 Aug 6;24:5462-5472. doi: 10.12659/MSM.911687. Med Sci Monit. 2018. PMID: 30080819 Free PMC article. Review.
-
Prognostic role of lncRNA TUG1 for cancer outcome: Evidence from 840 cancer patients.Oncotarget. 2017 Jul 25;8(30):50051-50060. doi: 10.18632/oncotarget.17844. Oncotarget. 2017. PMID: 28548946 Free PMC article.
-
Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis.BMC Cancer. 2022 Jan 3;22(1):10. doi: 10.1186/s12885-021-09068-w. BMC Cancer. 2022. PMID: 34979987 Free PMC article. Review.
Cited by
-
LncRNA SNHG1 Promotes the Progression of Pancreatic Cancer by Regulating FGFR1 Expression via Competitively Binding to miR-497.Front Oncol. 2022 Jan 24;12:813850. doi: 10.3389/fonc.2022.813850. eCollection 2022. Front Oncol. 2022. PMID: 35141164 Free PMC article.
-
LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.Bioengineered. 2021 Dec;12(2):9239-9250. doi: 10.1080/21655979.2021.1996305. Bioengineered. 2021. PMID: 34806925 Free PMC article.
-
Regulation of microRNA-497 expression in human cancer.Oncol Lett. 2021 Jan;21(1):23. doi: 10.3892/ol.2020.12284. Epub 2020 Nov 11. Oncol Lett. 2021. PMID: 33240429 Free PMC article. Review.
-
LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis.Biosci Rep. 2020 Aug 28;40(8):BSR20193532. doi: 10.1042/BSR20193532. Biosci Rep. 2020. PMID: 32785606 Free PMC article. Review.
-
The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression.Cell Prolif. 2020 Sep;53(9):e12887. doi: 10.1111/cpr.12887. Epub 2020 Aug 10. Cell Prolif. 2020. PMID: 32779318 Free PMC article. Review.
References
-
- Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–938. doi: 10.1016/j.molcel.2010.08.011. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- ZR2016HB08/Distinguished Middle-Aged and Young Scientist Encourage and Reward Foundation of Shandong Province
- 81600691/National Natural Science Foundation of China
- 2016GGB14019/Research and Development Project of Shandong Province
- 17-3-3-8-nsh/people's Livelihood Science and technology program of Qingdao
LinkOut - more resources
Full Text Sources
Miscellaneous